Chan KKW - Search Results

1

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.

Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Goldstein DA, et al. Among authors: chan kkw. Oncologist. 2017 Jun;22(6):694-699. doi: 10.1634/theoncologist.2016-0455. Epub 2017 Jun 7. Oncologist. 2017. PMID: 28592621 Free PMC article.

2

Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM. Chan KK, et al. J Clin Oncol. 2012 Apr 1;30(10):1064-71. doi: 10.1200/JCO.2011.36.8647. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393098

3

Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.

Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Zurawska U, et al. J Clin Oncol. 2012 Sep 10;30(26):3167-73. doi: 10.1200/JCO.2011.40.7510. Epub 2012 Jun 18. J Clin Oncol. 2012. PMID: 22711851

4

Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis.

Prica A, Chan K, Cheung M. Prica A, et al. Neuro Oncol. 2014 Oct;16(10):1384-91. doi: 10.1093/neuonc/nou057. Epub 2014 May 5. Neuro Oncol. 2014. PMID: 24799455 Free PMC article.

5

The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?

Lien K, Berry S, Ko YJ, Chan KK. Lien K, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):81-100. doi: 10.1586/14737167.2015.982100. Epub 2014 Nov 17. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25400031 Review.

6

Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma.

Look Hong NJ, Petrella T, Chan K. Look Hong NJ, et al. J Surg Oncol. 2015 Mar 15;111(4):423-30. doi: 10.1002/jso.23833. Epub 2014 Nov 24. J Surg Oncol. 2015. PMID: 25422047

7

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.

Lee EK, Wong WW, Trudeau ME, Chan KK. Lee EK, et al. Breast Cancer Res Treat. 2015 Feb;150(1):169-80. doi: 10.1007/s10549-015-3309-3. Epub 2015 Feb 19. Breast Cancer Res Treat. 2015. PMID: 25694355

8

Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.

Prica A, Chan K, Cheung M. Prica A, et al. Cancer. 2015 Aug 1;121(15):2637-45. doi: 10.1002/cncr.29372. Epub 2015 Apr 15. Cancer. 2015. PMID: 25877511 Free article.

9

Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.

Yu JL, Chan K, Kurin M, Pasetka M, Kiss A, Sridhar SS, Warner E. Yu JL, et al. Breast J. 2015 Nov-Dec;21(6):658-64. doi: 10.1111/tbj.12501. Epub 2015 Sep 20. Breast J. 2015. PMID: 26387577

10

A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer.

Kumachev A, Yan M, Berry S, Ko YJ, Martinez MC, Shah K, Chan KK. Kumachev A, et al. PLoS One. 2015 Oct 16;10(10):e0140187. doi: 10.1371/journal.pone.0140187. eCollection 2015. PLoS One. 2015. PMID: 26474403 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters